BI 2536

Catalog No.S1109

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Cited by 91 Publications

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )
Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )
Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )
Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnPZ3d{UUN3ME2wMlAxPzd4IN88US=>	MoLJV2FPT0WU
ACN	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7kUGNKSzVyPUCuNFA5PDNizszN	MWXTRW5ITVJ?
TE-8	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwMEC5OFEh\|ryP	M1jJ[XNCVkeHUh?=
LC-2-ad	NF\YV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV61T2V2UUN3ME2wMlAyODl\|IN88US=>	NUfFTZBrW0GQR1XS
ALL-PO	M2rxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVyzUXYzUUN3ME2wMlAyOyEQvF2=	MYLTRW5ITVJ?
EW-16	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlq1TWM2OD1yLkCxN\|M3KM7:TR?=	MUfTRW5ITVJ?
KM12	M1vGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUT1fpJQUUN3ME2wMlAyOzR6IN88US=>	MWPTRW5ITVJ?
GI-1	NHKzcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPQTWM2OD1yLkCxN\|g{KM7:TR?=	MkfjV2FPT0WU
LS-411N	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;GO2lEPTB;MD6wNVQxPyEQvF2=	MWfTRW5ITVJ?
ES8	NUC4U25ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTITWM2OD1yLkCxOFk1KM7:TR?=	NIXr[ZZUSU6JRWK=
SNU-C2B	NHP2VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHkNZlKSzVyPUCuNFE2OjZizszN	MWjTRW5ITVJ?
CESS	NXTwZnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTBwMEG2NFIh\|ryP	NVrWOpRGW0GQR1XS
697	NWTQUmZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jDV2lEPTB;MD6wNVY3QCEQvF2=	NUe3enVWW0GQR1XS
NCI-H1963	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj5TWM2OD1yLkCxOlc{KM7:TR?=	M2\0OXNCVkeHUh?=
IA-LM	M1LoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rwemlEPTB;MD6wNVY5QCEQvF2=	NV70WJZEW0GQR1XS
SW954	NHjv[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\BTWM2OD1yLkCxO\|A2KM7:TR?=	NIjRTohUSU6JRWK=
RL95-2	NXjGTo1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHTZplKSzVyPUCuNFE4OzhizszN	NFHn[INUSU6JRWK=
LXF-289	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{X1VGlEPTB;MD6wNVc4KM7:TR?=	MYXTRW5ITVJ?
OCUB-M	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\5TWM2OD1yLkCxPFI3KM7:TR?=	M2DD[3NCVkeHUh?=
RKO	M4HYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHkTWM2OD1yLkCxPVg4KM7:TR?=	NEXoeVlUSU6JRWK=
LOUCY	NGr1VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HM[2lEPTB;MD6wNlA2KM7:TR?=	MVHTRW5ITVJ?
NOS-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnqyTWM2OD1yLkCyNFk{KM7:TR?=	NIrJdJZUSU6JRWK=
A4-Fuk	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHUTWM2OD1yLkCyNlE5KM7:TR?=	Moq5V2FPT0WU
A388	NXHGOW5LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHybZJKSzVyPUCuNFIzOjdizszN	NXr2PZBuW0GQR1XS
TE-9	NHvseWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rEVGlEPTB;MD6wNlI3OSEQvF2=	MY\TRW5ITVJ?
KURAMOCHI	MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;sO2lEPTB;MD6wNlI5PSEQvF2=	MXHTRW5ITVJ?
KALS-1	NVrlZ5VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXmxTlViUUN3ME2wMlAzOzN6IN88US=>	NHLIOlRUSU6JRWK=
HOP-62	NXq0XFdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf6TWM2OD1yLkCyOFIh\|ryP	NV:4U\|ZWW0GQR1XS
RPMI-8402	MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTBwMEK1NFgh\|ryP	NHzZ[pZUSU6JRWK=
TE-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHVTWM2OD1yLkCyOVEzKM7:TR?=	MYTTRW5ITVJ?
CCRF-CEM	NGLOSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3SwWGlEPTB;MD6wNlU1OyEQvF2=	NYXFflJ5W0GQR1XS
HUTU-80	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\k[lhKSzVyPUCuNFI3OjRizszN	M3TQdXNCVkeHUh?=
NCI-H1648	M4nWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPqWHpKSzVyPUCuNFI3PDdizszN	MWPTRW5ITVJ?
HCE-4	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTBwMEK2PFIh\|ryP	M1zneHNCVkeHUh?=
ETK-1	NGnOcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX5e29GUUN3ME2wMlAzPzN4IN88US=>	NFrkO41USU6JRWK=
TE-15	M2XKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwMEK3N\|gh\|ryP	MYjTRW5ITVJ?
BE-13	M1LWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3f0VWlEPTB;MD6wNlc1KM7:TR?=	NWXIcJR6W0GQR1XS
KE-37	NVP4TIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTBwMEK3OFEh\|ryP	MXrTRW5ITVJ?
NCI-H1355	NF\XO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTBwMEK3PFMh\|ryP	NEnQcHBUSU6JRWK=
TE-11	MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;TUWlEPTB;MD6wNlgxQSEQvF2=	M1HueHNCVkeHUh?=
BL-70	NGrubIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHMbnpIUUN3ME2wMlAzQDV5IN88US=>	Mnj0V2FPT0WU
ES6	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnLeII3UUN3ME2wMlAzQDhzIN88US=>	MYjTRW5ITVJ?
GT3TKB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnXbZhKSzVyPUCuNFI6PTNizszN	MoDQV2FPT0WU
LB647-SCLC	NWDGSGZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTBwMEOxPVUh\|ryP	NUDsXJRUW0GQR1XS
NB13	M3jaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfPTWM2OD1yLkCzN\|E3KM7:TR?=	M4TxW3NCVkeHUh?=
ST486	M{L4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHv6dnZKSzVyPUCuNFM{OzdizszN	MoLNV2FPT0WU
NCI-H82	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPzTWM2OD1yLkCzN\|Q{KM7:TR?=	NWK5V45RW0GQR1XS
NTERA-S-cl-D1	NEOzeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mon2TWM2OD1yLkCzN\|k6KM7:TR?=	MoTKV2FPT0WU
ES4	Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXX0S4xuUUN3ME2wMlA{PDZ\|IN88US=>	Mn7OV2FPT0WU
SK-NEP-1	NV:5fodoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXv2TWJRUUN3ME2wMlA{PDl7IN88US=>	MUnTRW5ITVJ?
Becker	NWHvXplsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\GbmlEPTB;MD6wN\|U2PSEQvF2=	MmPyV2FPT0WU
A101D	M161O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTBwMEO3OFgh\|ryP	M2P4[3NCVkeHUh?=
SK-UT-1	NHPC[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HlWmlEPTB;MD6wN\|c4PCEQvF2=	M4P2bXNCVkeHUh?=
SW982	NIHLRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwMEO3PUDPxE1?	M1;VW3NCVkeHUh?=
TE-10	NH7CRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrqTWM2OD1yLkC0NFQ3KM7:TR?=	NG\peWtUSU6JRWK=
OVCAR-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjYTWM2OD1yLkC0NFU6KM7:TR?=	MVrTRW5ITVJ?
KP-N-YS	M1G4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nST2lEPTB;MD6wOFA5PSEQvF2=	M2XwRXNCVkeHUh?=
BL-41	NH35RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2SwZWlEPTB;MD6wOFEzPSEQvF2=	NXnm[nJ6W0GQR1XS
MZ1-PC	NYTOU4w5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT1WYZRUUN3ME2wMlA1OTJ5IN88US=>	NEDuUFVUSU6JRWK=
PF-382	Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwMESxPVgh\|ryP	M3T6e3NCVkeHUh?=
MOLT-13	Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTCN\|NKSzVyPUCuNFQzOzhizszN	NVfSW297W0GQR1XS
HCC1599	NFXsTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13nW2lEPTB;MD6wOFI2QCEQvF2=	M3X6e3NCVkeHUh?=
IST-MEL1	M1zJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jrUGlEPTB;MD6wOFQ1OiEQvF2=	MYTTRW5ITVJ?
LU-139	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPxRZZIUUN3ME2wMlA1PDR{IN88US=>	M37NOHNCVkeHUh?=
MS-1	M2T1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3TbIxiUUN3ME2wMlA1PzBzIN88US=>	M370fHNCVkeHUh?=
MFH-ino	NXS3RWczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHwXWVUUUN3ME2wMlA2ODB\|IN88US=>	M2XKZ3NCVkeHUh?=
IMR-5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTiVIxvUUN3ME2wMlA2ODJzIN88US=>	NUX1VYM1W0GQR1XS
TE-5	M1TGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;BPZFKSzVyPUCuNFUxPjNizszN	NUnLPYp7W0GQR1XS
DJM-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPNTWM2OD1yLkC1NVQzKM7:TR?=	MV;TRW5ITVJ?
NB17	M17BbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLZRVd4UUN3ME2wMlA2OjB5IN88US=>	NXnKPGYzW0GQR1XS
KARPAS-45	M3XZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTBwMEWzOVgh\|ryP	M4PadXNCVkeHUh?=
TGBC1TKB	NWXLWnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLPV\|FKSzVyPUCuNFU1ODVizszN	MmnCV2FPT0WU
ML-2	M3nX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGOxdpZKSzVyPUCuNFU1OTRizszN	MV;TRW5ITVJ?
no-10	NX;iOotDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;O[2lEPTB;MD6wOVQ4PCEQvF2=	MXzTRW5ITVJ?
CTV-1	M3fjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTBwMEW1NFIh\|ryP	NIrVdJNUSU6JRWK=
SJSA-1	NEi5NJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{naO2lEPTB;MD6wOVUzKM7:TR?=	MUjTRW5ITVJ?
HC-1	M3\wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\TRWJ4UUN3ME2wMlA2PTl5IN88US=>	M4LienNCVkeHUh?=
TE-12	NYjOOo9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\2WVFrUUN3ME2wMlA2PjF\|IN88US=>	MmXCV2FPT0WU
KY821	NYHE[YlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\idHRUUUN3ME2wMlA2PjN{IN88US=>	NI\LWHpUSU6JRWK=
TALL-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrROIVKSzVyPUCuNFU4ODhizszN	MX7TRW5ITVJ?
DEL	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnH5TWM2OD1yLkC1O\|A6KM7:TR?=	M4HuVnNCVkeHUh?=
TE-6	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfMbZVKSzVyPUCuNFU4OjJizszN	M2X6b3NCVkeHUh?=
SK-LMS-1	NIS1OoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXw[\|hMUUN3ME2wMlA2QDB3IN88US=>	Mnr4V2FPT0WU
EW-1	M3HqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;6b5VKSzVyPUCuNFU5OzdizszN	Mn:0V2FPT0WU
8-MG-BA	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;leI9KSzVyPUCuNFU5PTFizszN	Ml7mV2FPT0WU
NALM-6	M3y1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwMEW5O\|Mh\|ryP	MWrTRW5ITVJ?
LB771-HNC	M4SxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTBwMEW5O\|kh\|ryP	NYDycoVxW0GQR1XS
HT-144	M17M[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;PTWM2OD1yLkC2NVMh\|ryP	MVnTRW5ITVJ?
KM-H2	M2Trcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\3cWlEPTB;MD6wOlIzOSEQvF2=	MkS1V2FPT0WU
SF268	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TJTWlEPTB;MD6wOlI5PiEQvF2=	MmXQV2FPT0WU
RS4-11	NHXHSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3flZ2lEPTB;MD6wOlMxPCEQvF2=	MkO1V2FPT0WU
MHH-PREB-1	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrRS\|hKSzVyPUCuNFY{OTlizszN	M4i0XXNCVkeHUh?=
ATN-1	NVXaWGtPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[xTWM2OD1yLkC2N\|Q2KM7:TR?=	NYTIPXlHW0GQR1XS
BB30-HNC	Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1P0XGlEPTB;MD6wOlQ{PiEQvF2=	NFzLV2NUSU6JRWK=
CPC-N	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwME[1NlQh\|ryP	MV\TRW5ITVJ?
NB1	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwME[2NVMh\|ryP	NH3zVmRUSU6JRWK=
KS-1	NXTu[mJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\nTWM2OD1yLkC2O\|Q5KM7:TR?=	MljsV2FPT0WU
RXF393	NHzs[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHJZWppUUN3ME2wMlA3PzZ2IN88US=>	MmHBV2FPT0WU
IST-SL2	NHi2fINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDlTWM2OD1yLkC3NFA1KM7:TR?=	MmGwV2FPT0WU
GI-ME-N	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrRTWM2OD1yLkC3Nlg3KM7:TR?=	NFjhfXhUSU6JRWK=
VA-ES-BJ	M1nVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTBwMEe0O\|Uh\|ryP	MVnTRW5ITVJ?
NCI-H1581	NUG4VlJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXlTWM2OD1yLkC3OFc5KM7:TR?=	MkD4V2FPT0WU
U-266	M{XsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPGXG9KSzVyPUCuNFc1QTdizszN	M2DQfnNCVkeHUh?=
DMS-114	NX\hbXBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYL1OGdoUUN3ME2wMlA4PTJ6IN88US=>	MlHpV2FPT0WU
NCI-H187	NU\HS49HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkj6TWM2OD1yLkC3O\|I3KM7:TR?=	M3;2NnNCVkeHUh?=
SW962	M4f6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HnVGlEPTB;MD6wO\|g{QSEQvF2=	NVznOZFMW0GQR1XS
MONO-MAC-6	NHy4fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XPSGlEPTB;MD6wO\|k5PiEQvF2=	NX;HSXNIW0GQR1XS
MOLT-16	NULFV5lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLTNYNKSzVyPUCuNFgyOjFizszN	NFPJN3FUSU6JRWK=
KNS-42	NH;WT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3u0[2lEPTB;MD6wPFE3OSEQvF2=	MmrxV2FPT0WU
CMK	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTTZ4FEUUN3ME2wMlA5OjJ3IN88US=>	MnjXV2FPT0WU
Ramos-2G6-4C10	NETtSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwMEiyNlUh\|ryP	M4riZ3NCVkeHUh?=
Daudi	NGrmOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\QTWM2OD1yLkC4NlU3KM7:TR?=	NHTmNpdUSU6JRWK=
NCI-H510A	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWO3[mxCUUN3ME2wMlA5OzN4IN88US=>	MX;TRW5ITVJ?
LB831-BLC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK5d2YyUUN3ME2wMlA5PTZzIN88US=>	NUmwUWlXW0GQR1XS
HEL	NIOzZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwMEi2Olgh\|ryP	NInse2ZUSU6JRWK=
LU-134-A	NWPkZpM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXnZng6UUN3ME2wMlA5PzB6IN88US=>	MXjTRW5ITVJ?
NCI-H1694	M4XiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXuNGljUUN3ME2wMlA5PzR2IN88US=>	M3zrbXNCVkeHUh?=
KGN	Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DKW2lEPTB;MD6wPFc2QSEQvF2=	MlrOV2FPT0WU
A253	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfROHd2UUN3ME2wMlA5QDJ{IN88US=>	MojqV2FPT0WU
DG-75	NF3wVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\WTWM2OD1yLkC4PVIzKM7:TR?=	M{jGd3NCVkeHUh?=
MOLT-4	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfjU\|U2UUN3ME2wMlA5QTh\|IN88US=>	NIXr[5ZUSU6JRWK=
NCI-SNU-5	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\0dlllUUN3ME2wMlA6OjV6IN88US=>	MW\TRW5ITVJ?
ONS-76	NHLkfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLNclR1UUN3ME2wMlA6Ojd4IN88US=>	NV7hSIV7W0GQR1XS
NCI-H446	NITZR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MontTWM2OD1yLkC5OFYzKM7:TR?=	M37xWHNCVkeHUh?=
COR-L279	M1L3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTBwMEm1OVYh\|ryP	M36wW3NCVkeHUh?=
Calu-6	NIDMdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTBwMEm1PVgh\|ryP	MlHtV2FPT0WU
BC-3	M2\2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jz[WlEPTB;MD6wPVY3OiEQvF2=	MVzTRW5ITVJ?
NCI-H2126	MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2KzfGlEPTB;MD6wPVc6OSEQvF2=	M1nUenNCVkeHUh?=
NCI-H1882	NUHJdHZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXv6N\|BuUUN3ME2wMlA6QDB7IN88US=>	NF[0XI1USU6JRWK=
BB65-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHuTWM2OD1yLkGwNlk1KM7:TR?=	NWnrOGM2W0GQR1XS
DU-4475	NFvLOJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnSxTWM2OD1yLkGwOFA4KM7:TR?=	Mn7nV2FPT0WU
NCI-H526	NXvHZVVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkW3TWM2OD1yLkGwOFQh\|ryP	M3r4ZXNCVkeHUh?=
NEC8	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTuTWM2OD1yLkGwOVI2KM7:TR?=	NFPtdZRUSU6JRWK=
NCI-H1304	M37s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrPSVFKSzVyPUCuNVA2QTRizszN	MXrTRW5ITVJ?
L-540	NU\vSnhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfvSI1KSzVyPUCuNVA4ODhizszN	NGj5bYNUSU6JRWK=
NCI-SNU-16	NGPC[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHCTWM2OD1yLkGwO\|QzKM7:TR?=	MnP0V2FPT0WU
HD-MY-Z	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHxTWM2OD1yLkGwPFU3KM7:TR?=	M36xOnNCVkeHUh?=
K-562	M4PsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3jdlZKSzVyPUCuNVA5PThizszN	M3LLW3NCVkeHUh?=
JAR	M3rJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTBwMUC5NlUh\|ryP	NVHuRVdPW0GQR1XS
MZ2-MEL	NEXRVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXKXINKSzVyPUCuNVExPSEQvF2=	M3jsSXNCVkeHUh?=
L-363	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfTe4VKSzVyPUCuNVExPzlizszN	MmPpV2FPT0WU
BV-173	MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPNTWM2OD1yLkGxNlQ{KM7:TR?=	MnTOV2FPT0WU
NCI-H524	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjUXnoxUUN3ME2wMlEyOjd2IN88US=>	MofnV2FPT0WU
EoL-1-cell	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXjUo1KSzVyPUCuNVE3PzJizszN	NIn2WIhUSU6JRWK=
K052	NH3VbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXWwe5JxUUN3ME2wMlEyPzF{IN88US=>	M4ixZnNCVkeHUh?=
TK10	NYO3ZWJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfNTWM2OD1yLkGxO\|I5KM7:TR?=	NVrB[5JqW0GQR1XS
KU812	NXLaU5hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG[4U3JKSzVyPUCuNVIxPDRizszN	MlLoV2FPT0WU
RPMI-8226	NVHRPG44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXxT3FtUUN3ME2wMlEzODV{IN88US=>	MoC2V2FPT0WU
MZ7-mel	NVnmUHdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvOTWM2OD1yLkGyNlM4KM7:TR?=	M2fsVXNCVkeHUh?=
SK-PN-DW	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPzXYxKSzVyPUCuNVIzQDdizszN	MnTmV2FPT0WU
SR	NED1NYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPoflRFUUN3ME2wMlEzPDRzIN88US=>	M3HDVHNCVkeHUh?=
RPMI-6666	NV30bokyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTBwMUK3OFMh\|ryP	M1LNSnNCVkeHUh?=
no-11	NG\PV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHK0SGNKSzVyPUCuNVI5PjlizszN	NEPhU4tUSU6JRWK=
EW-3	M3v0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmK2TWM2OD1yLkGyPFk{KM7:TR?=	MlLXV2FPT0WU
LAMA-84	NWnvRlEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLPTWM2OD1yLkGzNVg4KM7:TR?=	MX3TRW5ITVJ?
HT	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoKyTWM2OD1yLkGzOVc1KM7:TR?=	MWnTRW5ITVJ?
KP-N-RT-BM-1	M{PJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTBwMUO2NVIh\|ryP	MlLhV2FPT0WU
NCI-H747	NHnNN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV35b3ozUUN3ME2wMlE{PyEQvF2=	M33vcnNCVkeHUh?=
NCCIT	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTBwMUO5N\|kh\|ryP	MlGxV2FPT0WU
MLMA	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XQ[GlEPTB;MD6xOFE3PyEQvF2=	Ml\kV2FPT0WU
LP-1	NELWSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMUSyOEDPxE1?	NHnGU3RUSU6JRWK=
CAL-148	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHIfXVwUUN3ME2wMlE1PDh\|IN88US=>	MX\TRW5ITVJ?
GB-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHwcW5KSzVyPUCuNVQ2OjZizszN	MlrvV2FPT0WU
COR-L88	M4LrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTBwMUS4NFIh\|ryP	NUe0eWR3W0GQR1XS
NKM-1	NFfkO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfZTWM2OD1yLkG0PVA3KM7:TR?=	MYLTRW5ITVJ?
NB5	MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1SwcmlEPTB;MD6xOVQ3OiEQvF2=	NED6TmpUSU6JRWK=
SH-4	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ixeWlEPTB;MD6xOVQ3PiEQvF2=	NXnQ[JJtW0GQR1XS
EM-2	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDjV\|Q3UUN3ME2wMlE2PDZ5IN88US=>	M4PSOnNCVkeHUh?=
TGBC24TKB	NYnhbZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XTZ2lEPTB;MD6xOVY2QSEQvF2=	NWDuUJR6W0GQR1XS
SCLC-21H	NES4Z5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfrUnhyUUN3ME2wMlE2PzB{IN88US=>	NHLXUmFUSU6JRWK=
COLO-684	M1TqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HxT2lEPTB;MD6xOVczOSEQvF2=	NVLxR49YW0GQR1XS
KINGS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwMUW5NUDPxE1?	NEe1ZnRUSU6JRWK=
LS-123	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTvTWM2OD1yLkG1PVE4KM7:TR?=	NYnHc\|RGW0GQR1XS
MC116	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULZflFoUUN3ME2wMlE3OTV6IN88US=>	NW\pcZgxW0GQR1XS
SU-DHL-1	NH3NZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTBwMU[yNFYh\|ryP	M33YSXNCVkeHUh?=
NCI-H64	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTBwMU[zOFch\|ryP	M4\QWnNCVkeHUh?=
HCE-T	M1;sfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XsOmlEPTB;MD6xOlUxPCEQvF2=	NVTsS2pUW0GQR1XS
LOXIMVI	M33oOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYeyTYg6UUN3ME2wMlE3QTR7IN88US=>	NUL2[5k6W0GQR1XS
ARH-77	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnITWM2OD1yLkG3N\|c6KM7:TR?=	M3PqfHNCVkeHUh?=
DOHH-2	NEe4emZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D1e2lEPTB;MD6xO\|Y4OiEQvF2=	M1\xWHNCVkeHUh?=
COLO-320-HSR	NXPtRlFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DqPGlEPTB;MD6xPFE2PCEQvF2=	M1nrS3NCVkeHUh?=
NB6	NUfrV29{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TtNWlEPTB;MD6xPFU3PiEQvF2=	M1PlRXNCVkeHUh?=
L-428	Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlOyTWM2OD1yLkG4PFE{KM7:TR?=	NIPNSJRUSU6JRWK=
SNB75	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwMUi4NlQh\|ryP	NFznNGVUSU6JRWK=
NCI-H2141	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXyXFRKSzVyPUCuNVkxOTFizszN	NWjOO5ZxW0GQR1XS
KARPAS-299	NUPVTVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEK2SVVKSzVyPUCuNVkzPDFizszN	MoXWV2FPT0WU
LC4-1	NXTETFFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTBwMUm1NFIh\|ryP	M3X1fnNCVkeHUh?=
UACC-257	M4WybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7p[HBKSzVyPUCuNVk6PDdizszN	MlzaV2FPT0WU
EVSA-T	M{TKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnFNnRvUUN3ME2wMlIxOzF{IN88US=>	MonsV2FPT0WU
JiyoyeP-2003	MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTFUFRXUUN3ME2wMlIxPDd5IN88US=>	NXPCUGdqW0GQR1XS
NCI-H720	NXriUFQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LuW2lEPTB;MD6yNFUzPSEQvF2=	NEPNfGxUSU6JRWK=
GAK	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTBwMkGxPFkh\|ryP	NEXQOYhUSU6JRWK=
HH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIT2W5VKSzVyPUCuNlE1ODVizszN	MorZV2FPT0WU
NCI-H1436	NVi5UoZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLGPWdHUUN3ME2wMlIyPDZ2IN88US=>	Mki3V2FPT0WU
GR-ST	NUPIPW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHixN2hKSzVyPUCuNlE1QDhizszN	NH7JbYJUSU6JRWK=
BC-1	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjXcGlKSzVyPUCuNlI3OTZizszN	NGjsTppUSU6JRWK=
SIG-M5	NWDOUVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\VTWM2OD1yLkKyO\|I4KM7:TR?=	NFPPOZZUSU6JRWK=
NCI-H345	M2ftbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjDV3NKSzVyPUCuNlM5ODVizszN	NUT6dVEyW0GQR1XS
OPM-2	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFr2[2FKSzVyPUCuNlM5QDJizszN	NFHQSHJUSU6JRWK=
LB1047-RCC	NHPadHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfyeIRKSzVyPUCuNlQ1OSEQvF2=	NYfvTZhoW0GQR1XS
CTB-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIW2V29KSzVyPUCuNlQ1QTNizszN	MYfTRW5ITVJ?
A3-KAW	NXi4NoV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnrTWM2OD1yLkK1N\|QyKM7:TR?=	MV7TRW5ITVJ?
SF126	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTBwMkWzPFMh\|ryP	NWfOcIYxW0GQR1XS
KARPAS-422	NHLjUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDOTWM2OD1yLkK1OFM2KM7:TR?=	NGnESFhUSU6JRWK=
MEG-01	NGfm[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknvTWM2OD1yLkK1Olc{KM7:TR?=	MYrTRW5ITVJ?
NCI-H209	NH;oXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX5fXFZUUN3ME2wMlI3Ozd2IN88US=>	NHLBTG1USU6JRWK=
SBC-1	MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXETWM2OD1yLkK2OUDPxE1?	MX;TRW5ITVJ?
K5	M33JeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjHNJFOUUN3ME2wMlI3QTh2IN88US=>	NWW0bJBZW0GQR1XS
QIMR-WIL	NV6wOndYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTBwMkexOVUh\|ryP	M1[1ZXNCVkeHUh?=
NMC-G1	NGjkcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{X0UmlEPTB;MD6yPFIyPyEQvF2=	Mn;uV2FPT0WU
IST-MES1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3RcYhKSzVyPUCuNlkzOzhizszN	MWfTRW5ITVJ?
SW684	M4\sZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33YNGlEPTB;MD6zNFA1PyEQvF2=	NUnxXJd2W0GQR1XS
MV-4-11	NW\zUI0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[ze5FLUUN3ME2wMlMxPzh6IN88US=>	NInIXo9USU6JRWK=
LAN-6	NYjzbGxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITqbIxKSzVyPUCuN\|E2PzJizszN	NITUVYxUSU6JRWK=
RH-1	NVXp[2V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwM{G4O\|Eh\|ryP	MXjTRW5ITVJ?
CP66-MEL	NHTOZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXrTWM2OD1yLkOxPFc5KM7:TR?=	NXXaZ\|NFW0GQR1XS
EC-GI-10	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwM{K5PFch\|ryP	MkD4V2FPT0WU
GDM-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn72TWM2OD1yLkOzNFU6KM7:TR?=	MYDTRW5ITVJ?
IST-SL1	NEjvRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[zWJNKSzVyPUCuN\|Q6OTRizszN	NIHWTJJUSU6JRWK=
KMOE-2	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwM{WxO\|Uh\|ryP	NGnLZmdUSU6JRWK=
OS-RC-2	M2DRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\wVWpKSzVyPUCuN\|U2PDRizszN	MWLTRW5ITVJ?
HDLM-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTBwM{e4NVQh\|ryP	NUf4OpZ5W0GQR1XS
DSH1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXsRVh[UUN3ME2wMlM5PjNzIN88US=>	NUXEUIZOW0GQR1XS
LS-1034	M33Fb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTBwM{i5OVQh\|ryP	NHXpTFdUSU6JRWK=
LB373-MEL-D	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDpTWM2OD1yLkO5NVk4KM7:TR?=	NWHp[Vd4W0GQR1XS
GOTO	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PzV2lEPTB;MD60NlEyQCEQvF2=	NXHF[2dbW0GQR1XS
MRK-nu-1	M1nqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfPTodKSzVyPUCuOFIzODVizszN	MUjTRW5ITVJ?
SK-MM-2	MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkC5TWM2OD1yLkSzOFQzKM7:TR?=	MV3TRW5ITVJ?
BOKU	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zETGlEPTB;MD60N\|c6OiEQvF2=	M4DR[nNCVkeHUh?=
NOMO-1	NUD3VHdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTBwNEO4OkDPxE1?	NUn2RlB2W0GQR1XS
J-RT3-T3-5	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWmyeJVxUUN3ME2wMlQ1QDd6IN88US=>	M3joR3NCVkeHUh?=
COLO-668	M1;BTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonwTWM2OD1yLkS1OlY5KM7:TR?=	NUjVXpNoW0GQR1XS
SF539	M2rNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3UTWM2OD1yLkS4Olg1KM7:TR?=	MnnoV2FPT0WU
LB2518-MEL	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf5TWM2OD1yLkS5O\|A{KM7:TR?=	NWf4NIp2W0GQR1XS
TE-441-T	NIPKTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHObGo2UUN3ME2wMlUxOTJizszN	MUDTRW5ITVJ?
MDA-MB-134-VI	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rmOWlEPTB;MD61NFkzOSEQvF2=	MXzTRW5ITVJ?
SCC-3	M16weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnETWM2OD1yLkWxPFc{KM7:TR?=	NEnoTmFUSU6JRWK=
KLE	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTH[XI2UUN3ME2wMlUzOTdzIN88US=>	MVrTRW5ITVJ?
LB2241-RCC	NEH5SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHu2NnNKSzVyPUCuOVI2OjVizszN	M4i0OHNCVkeHUh?=
NCI-H1417	M3SwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moe5TWM2OD1yLkWzOFM2KM7:TR?=	MX7TRW5ITVJ?
NCI-H2081	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y1T2lEPTB;MD61PFYyOSEQvF2=	NGHGTpdUSU6JRWK=
NCI-H1522	NV74dWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzqTWM2OD1yLkW5N\|g{KM7:TR?=	NYTs[FZqW0GQR1XS
NCI-H889	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTEVm1KSzVyPUCuOVk5PDRizszN	MW\TRW5ITVJ?
CGTH-W-1	NIi4PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4[yUmlEPTB;MD62NFc2PSEQvF2=	NEKxWVFUSU6JRWK=
EB-3	MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTBwNkGxOVMh\|ryP	NUfLXYlmW0GQR1XS
D-336MG	NIfIZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PLPWlEPTB;MD62NVc6OSEQvF2=	MlvSV2FPT0WU
LC-1F	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDveoVKSzVyPUCuOlI2QTJizszN	NWPp[YdqW0GQR1XS
MHH-NB-11	NGXTfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDLdYxKSzVyPUCuOlM5ODFizszN	Ml2zV2FPT0WU
SK-N-FI	M3X3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTBwNkO5NUDPxE1?	MWPTRW5ITVJ?
NCI-H69	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjnVYZKSzVyPUCuOlQ5PzlizszN	MWTTRW5ITVJ?
SCH	Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M162WWlEPTB;MD62OlAzOyEQvF2=	NFzRUHZUSU6JRWK=
LS-513	NEXrTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTFOm9sUUN3ME2wMlY4OjV7IN88US=>	M2[3[3NCVkeHUh?=
CP67-MEL	NHWwUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnj3TWM2OD1yLk[3OVk3KM7:TR?=	Mo[2V2FPT0WU
GCIY	NHjye3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnzR3ZPUUN3ME2wMlcxOzZ\|IN88US=>	M4mxTHNCVkeHUh?=
SHP-77	MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwN{C3N\|Qh\|ryP	NW\2WGF{W0GQR1XS
EHEB	M1rCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PURmlEPTB;MD63NVg2PCEQvF2=	MVTTRW5ITVJ?
D-247MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofyTWM2OD1yLkezNlMzKM7:TR?=	M3LINXNCVkeHUh?=
Raji	NWjBU45{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTUcnZKSzVyPUCuO\|Q6QDlizszN	NYrE[Fh4W0GQR1XS
MPP-89	NIf4ephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jFU2lEPTB;MD63OVk4QCEQvF2=	MX;TRW5ITVJ?
EKVX	MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHDTWM2OD1yLke5NFc{KM7:TR?=	MW\TRW5ITVJ?
HCC2218	M37wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTBwN{mxN\|Eh\|ryP	NF;RSG5USU6JRWK=
KNS-81-FD	NV7tZngzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTBwOEGwNVEh\|ryP	NYPzV\|ViW0GQR1XS
HCC2157	NFnnN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPteIRKSzVyPUCuPFQ6PTFizszN	M4L3OXNCVkeHUh?=
BT-474	Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHTTWM2OD1yLki4PFU1KM7:TR?=	Mk[xV2FPT0WU
NCI-H748	NV6zc4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TL[mlEPTB;MD65NVIh\|ryP	M2PWWHNCVkeHUh?=
EW-24	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2WxTmlEPTB;MD65NlAxOiEQvF2=	MUjTRW5ITVJ?
D-263MG	NXPId\|hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\uTWM2OD1yLkm0OVEzKM7:TR?=	M3G0bHNCVkeHUh?=
OMC-1	NXjDTnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\FOoJKSzVyPUCuPVY{PzNizszN	NVf1VphZW0GQR1XS
NCI-H2196	M2DwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITVXGNKSzVyPUCuPVc4PzdizszN	MXnTRW5ITVJ?
HAL-01	NGfobnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfVXpAyUUN3ME2wMlk6QDd{IN88US=>	NYKxTIdHW0GQR1XS
NCI-H2107	NH7XeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHUUWNIUUN3ME2xMlAyQDV2IN88US=>	M{DmenNCVkeHUh?=
LB996-RCC	NU[5W4dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEiyd5NKSzVyPUGuNFgxPTFizszN	NYPtS2VHW0GQR1XS
NCI-H1395	NGTTOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3WTWM2OD1zLkGwOlch\|ryP	MXHTRW5ITVJ?
CHP-126	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTFwMU[xPVkh\|ryP	MVXTRW5ITVJ?
NB69	NUTqRYpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTFwMk[xOFgh\|ryP	NUnFVYx3W0GQR1XS
CAS-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjyWG1KSzVyPUGuN\|QzOzFizszN	NWPVT49tW0GQR1XS
JVM-3	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnRSYxKSzVyPUGuOFc5PTVizszN	NXr0TVFsW0GQR1XS
DMS-153	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjrTJVtUUN3ME2xMlU4Pjd2IN88US=>	NXnLbGVyW0GQR1XS
SK-MEL-2	NGfxXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXZSXZ4UUN3ME2xMlcyPzh7IN88US=>	MX7TRW5ITVJ?
NCI-H1155	M3LBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLZOXVKSzVyPUGuO\|M3PzZizszN	MkfNV2FPT0WU
NCI-H1092	NGLjOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nmN2lEPTB;MT63OlE5OiEQvF2=	MXTTRW5ITVJ?
LU-165	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTFwOE[0O\|Yh\|ryP	NYLjUHVrW0GQR1XS
HL-60	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTFwOUm5NFgh\|ryP	Mlv4V2FPT0WU
REH	NXrHeGF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLkTWM2OD1{LkCwOVgzKM7:TR?=	Mln6V2FPT0WU
JVM-2	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnWb3d7UUN3ME2yMlA3OTN3IN88US=>	MnfiV2FPT0WU
MN-60	NEHN[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj2eI9KSzVyPUKuNVc{ODhizszN	Mmf0V2FPT0WU
SCC-15	M2nhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJwMkCyO{DPxE1?	M33vUHNCVkeHUh?=
SNU-C1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXBb4VKSzVyPUKuNlE{PDNizszN	NXPLTWVnW0GQR1XS
SK-MEL-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfWRmdKSzVyPUKuN\|IxPDdizszN	MUHTRW5ITVJ?
TGW	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTJwM{WwNlch\|ryP	MlrOV2FPT0WU
CA46	M4fubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\VTWM2OD1{Lke1PVY4KM7:TR?=	MU\TRW5ITVJ?
NCI-H23	M{XvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;INGlEPTB;Mj64NFc6OSEQvF2=	NGj4cW9USU6JRWK=
MMAC-SF	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJwOE[2Nlgh\|ryP	MWHTRW5ITVJ?
NCI-H2171	M165T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTNwMEO0OFgh\|ryP	MYHTRW5ITVJ?
A704	NE\rOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX62Zpl4UUN3ME2zMlE1OTl2IN88US=>	MkftV2FPT0WU
DB	NI\uUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfZTWM2OD1\|LkK1OVc3KM7:TR?=	NHTNWFZUSU6JRWK=
NCI-H719	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPGTWM2OD1\|LkOwN\|g1KM7:TR?=	NEjGOphUSU6JRWK=
MC-CAR	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTNwNUS4NVch\|ryP	MVvTRW5ITVJ?
SIMA	MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTCbG96UUN3ME2zMlU5PDF4IN88US=>	MVrTRW5ITVJ?
SW872	M1PQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XjTWlEPTB;Mz63PFExOSEQvF2=	MWrTRW5ITVJ?
HCC1187	M3[3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTNwN{izNVUh\|ryP	M4nGSXNCVkeHUh?=
EW-13	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnHUWtKSzVyPUOuPFM1OTdizszN	MmDYV2FPT0WU
NCI-SNU-1	NGHYToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLGZo9mUUN3ME20MlIyQTl7IN88US=>	MUDTRW5ITVJ?
NCI-H226	M3TQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkiwTWM2OD12LkOzOlA3KM7:TR?=	NIC5WG9USU6JRWK=
RPMI-8866	NFG1cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmm2TWM2OD12LkO2NFI6KM7:TR?=	NVXodVBsW0GQR1XS
OCI-AML2	MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\XTWM2OD12LkW1NlMh\|ryP	Ml3VV2FPT0WU
LU-65	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlu2TWM2OD12LkmzNFM{KM7:TR?=	MofhV2FPT0WU
SK-N-DZ	NXrKfYM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPMSpNVUUN3ME21MlY{PDZ3IN88US=>	MYDTRW5ITVJ?
NB14	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3lRW9lUUN3ME21Mlk4OTN3IN88US=>	M4fFSXNCVkeHUh?=
COLO-829	M3XjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XVZWlEPTB;Nj6zN\|M2QSEQvF2=	MnW3V2FPT0WU
MHH-CALL-2	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFq1fpZKSzVyPU[uOVE2ODhizszN	NHvHVVBUSU6JRWK=
NCI-H1770	M2frWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG3dmVKSzVyPU[uOlY6ODRizszN	MXHTRW5ITVJ?
ECC4	M4LHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnCTWM2OD14LkiyNVc6KM7:TR?=	M2LFTHNCVkeHUh?=
A498	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LSbmlEPTB;Nj64O\|E6OiEQvF2=	MmqwV2FPT0WU
DMS-79	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjzW4tqUUN3ME23MlA1PTF{IN88US=>	MmLoV2FPT0WU
P30-OHK	NE\Fe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorOTWM2OD15LkKxPVA3KM7:TR?=	M1rJSHNCVkeHUh?=
D-502MG	MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGmyS4tKSzVyPUeuPVg{PiEQvF2=	MWHTRW5ITVJ?
RCC10RGB	NVPBcWxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRThwME[yPEDPxE1?	NF76Z5NUSU6JRWK=
U-698-M	NWnnOZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfqfXJKSzVyPUiuNlkzOjZizszN	NH;CfXFUSU6JRWK=
BB49-HNC	NFHNS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTTcWVxUUN3ME25MlQzOjZ3IN88US=>	NXi5ZmtrW0GQR1XS
ES1	NUTqT3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTZTWM2OD17Lk[4PVU3KM7:TR?=	NX7mNlA5W0GQR1XS
MFM-223	NY\4WpJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjPfWdKSzVyPUGwMlk6OjdizszN	NXfleoVsW0GQR1XS
C2BBe1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HGSmlEPTB;MUGuN\|UzOyEQvF2=	M{\Fb3NCVkeHUh?=
EB2	MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTF{Lk[4PFEh\|ryP	MmLZV2FPT0WU
C8166	M2Lkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTF\|LkizNFMh\|ryP	NHuzdIZUSU6JRWK=
ES3	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTF\|Lkm5O\|ch\|ryP	NITHbZZUSU6JRWK=
NCI-H1650	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\5cWlEPTB;MU[uN\|c3PSEQvF2=	Ml3tV2FPT0WU
Mo-T	NGPqcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHSTWM2OD1zNz60NFI6KM7:TR?=	M3G3cnNCVkeHUh?=
NB7	M3LTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;ReGp3UUN3ME2xO{44PDZ5IN88US=>	NXvqcG5zW0GQR1XS
ES7	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnS5TWM2OD1zOT61OVA4KM7:TR?=	MnHWV2FPT0WU
ES5	NVricJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nvOGlEPTB;MkGuO\|Y4OSEQvF2=	MVPTRW5ITVJ?
MSTO-211H	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\2TGlEPTB;MkGuPFg2QCEQvF2=	M4\LU3NCVkeHUh?=
U-87-MG	MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTJ3LkG5OlYh\|ryP	NGLINHZUSU6JRWK=
THP-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfFTWM2OD1{OT63NlAyKM7:TR?=	NHLNWFZUSU6JRWK=
NB10	NUH3U3JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorFTWM2OD1\|MD6yOlk1KM7:TR?=	NV71R5l1W0GQR1XS
NH-12	M3XKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXriRoFjUUN3ME2zN{4zODF5IN88US=>	MVTTRW5ITVJ?
COLO-824	M{LPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPYcINKSzVyPUO0MlExODZizszN	MnznV2FPT0WU
SKM-1	M1zBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjpfW1KSzVyPUO3Mlg1OjJizszN	NHn5RlBUSU6JRWK=
NCI-H1838	NFrwUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\LTWM2OD1\|OD6zO\|k4KM7:TR?=	NVHSUWNMW0GQR1XS
RL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\qTWM2OD1\|OT6yOFc4KM7:TR?=	M3zxOHNCVkeHUh?=
COLO-800	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3VTWM2OD12MD6wO\|c{KM7:TR?=	NFjn[XVUSU6JRWK=
KG-1	Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\6dJVbUUN3ME20NE45QTV3IN88US=>	MUfTRW5ITVJ?
TUR	NXX2ToJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTRzLk[zPVkh\|ryP	M1y5SHNCVkeHUh?=
LNCaP-Clone-FGC	NIrmeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTRzLkmwNVch\|ryP	MkWyV2FPT0WU
NCI-H322M	M3nPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTR{LkW5PFQh\|ryP	MX3TRW5ITVJ?
LNCaP	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIr1epJKSzVyPUmxMlMhdk1?	MnOwNlU2ODVzN{S=
C4-2	MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDTTWM2OD16IH7N	M2rWOlI2PTB3MUe0
JURKAT	NUTFUZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmmyNlQhcA>?		Ml7ETWM2OD12MU[uOlYhdk1?	NF\QO4czPDVzOUm5OS=>
MOLT-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnfENlQhcA>?		MnrVTWM2OD1{OEWzMlUhdk1?	MVKyOFUyQTl7NR?=
REH	NIXIXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3z2V\|I1KGh?		NX;WNZdJUUN3ME2yPFcvPjhibl2=	NVvzNZpGOjR3MUm5PVU>
NALM-6	NV[ySGplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV[yOEBp		MUHJR\|UxRTN2M{OwJI5O	M4TkUlI1PTF7OUm1
RS 4;11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{LzUFI1KGh?		NVfyPJBSUUN3ME21NVkvODVibl2=	M2TiNVI1PTF7OUm1
697	Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmTvNlQhcA>?		NV;GbnllUUN3ME2yNVA4NjFibl2=	MWGyOFUyQTl7NR?=
SIL-ALL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mnf3NlQhcA>?		MY\JR\|UxRTF7OT63O{BvVQ>?	NV\zOoZ7OjR3MUm5PVU>
CEM	NHy3cItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVqyOEBp		NG\z[IpKSzVyPUWyMlE5KG6P	NGjPZpUzPDVzOUm5OS=>
P12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYLUOWpSOjRiaB?=		MlzQTWM2OD1\|OT6yO{BvVQ>?	MoLPNlQ2OTl7OUW=
NALM-16	M2mz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{DvZ\|I1KGh?		NF3FfZFKSzVyPUm2MlI5KG6P	MV2yOFUyQTl7NR?=
JURKAT	M3zT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnvvOFghcA>?		MXvJR\|UxRTF2Lki0JI5O	NF:wcmMzPDVzOUm5OS=>
MOLT-4	NWKzXZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXPGO5RyPDhiaB?=		M33nbWlEPTB;Mk[uOkBvVQ>?	MYGyOFUyQTl7NR?=
REH	NH\ZUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{XwelQ5KGh?		MWrJR\|UxRTR2LkexJI5O	MYOyOFUyQTl7NR?=
NALM-6	M{LKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYW0PEBp		NUTsRZRtUUN3ME2yN{4zPiCwTR?=	M3PmS\|I1PTF7OUm1
RS 4;11	NVLKS3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWm1SHoxPDhiaB?=		MWPJR\|UxRTF4ND6yPEBvVQ>?	M2rLTVI1PTF7OUm1
697	M2W0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVO0PEBp		MXHJR\|UxRTNyNT6zJI5O	M4C1dlI1PTF7OUm1
SIL-ALL	NYe0RZN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkHHOFghcA>?		M2jVNmlEPTB;N{SuOlIhdk1?	NX;QToJVOjR3MUm5PVU>
CEM	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV[0PEBp		NXXJN4NxUUN3ME2yOE42PSCwTR?=	MWeyOFUyQTl7NR?=
P12	NXnLWINJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1PudlQ5KGh?		NUnmTHY6UUN3ME2xPE41PiCwTR?=	NHzSd4kzPDVzOUm5OS=>
NALM-16	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVrP[WxFPDhiaB?=		NYrafW96UUN3ME22N{4zPCCwTR?=	NWD0Z3dtOjR3MUm5PVU>
JURKAT	M3q4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NW\n[mhYPzJiaB?=		MY\JR\|UxRTNwNkWgcm0>	MmXYNlQ2OTl7OUW=
MOLT-4	M4DBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUW3NkBp		NVLD[nB7UUN3ME23MlM6KG6P	MYSyOFUyQTl7NR?=
REH	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGD2bIU4OiCq		MnzoTWM2OD1zNj6wNUBvVQ>?	M3y5[\|I1PTF7OUm1
NALM-6	M{DvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUK3NkBp		Mn\pTWM2OD1zLke4JI5O	M2jTc\|I1PTF7OUm1
RS 4;11	M171Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWntXWJFPzJiaB?=		NVvrV5VuUUN3ME20MlM5KG6P	MlT0NlQ2OTl7OUW=
697	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWG3NkBp		MW\JR\|UxRTd2LkK4JI5O	NIq2cIEzPDVzOUm5OS=>
SIL-ALL	NWD3eZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHfnUGM4OiCq		NIrYfWNKSzVyPUeuNkBvVQ>?	NH3ES24zPDVzOUm5OS=>
CEM	NYf4W4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlLsO\|IhcA>?		NYjJW2xoUUN3ME21MlQzKG6P	NXTmN3dEOjR3MUm5PVU>
P12	Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUW3NkBp		NFjjb2VKSzVyPU[uN\|chdk1?	NFrHTXczPDVzOUm5OS=>
NALM-16	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MofLO\|IhcA>?		MYjJR\|UxRTd5LkezJI5O	MXWyOFUyQTl7NR?=
Y79	NXz1N\|dkSXCxcITvd4l{KEG\|c3H5	Mk\XNU02OCCwTR?=	MlvkNVIwOjRiaB?=	NEL3SlRFVVOR	MYLpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=	MoXuNlQ{PjZ4NkW=
WER-Rb-1	MVjBdI9xfG:\|aYOgRZN{[Xl?	MnzZNU02OCCwTR?=	M4DTSFEzNzJ2IHi=	NEXweGJFVVOR	MVfpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=	MUWyOFM3PjZ4NR?=
G7	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEOwRnFKSzVyPUOuN{BvVQ>?	Ml\lNlQzODR5M{O=
G166	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL5TWM2OD15LkCgcm0>	NUO1NnF1OjR{MES3N\|M>
CB660	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfRTWM2OD14LkSgcm0>	MnLBNlQzODR5M{O=
CB1117	NXfr[YFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTUOmZvUUN3ME2xOU43KG6P	MUCyOFIxPDd\|Mx?=
KB-3-1	NV3GPXVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX5TWM2OD1zLkS4JOKyKDBwNUOgcm0>	NFSz[GMzOzl4MkS0OS=>
KB-8-5-11	NVvrU4pGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPtblhKSzVyPUWuNFEhyrFiMj6wNUBvVQ>?	MoDONlM6PjJ2NEW=
KB-C-1	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXO4WXRIUUN3ME2xOk44PiEEsTC0MlUyKG6P	M3PneVI{QTZ{NES1
KB-V-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGL4bYJKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?=	MkHwNlM6PjJ2NEW=
OVCAR-8	MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGD1b5VKSzVyPUeuNVkhyrFiMz62NEBvVQ>?	MVmyN\|k3OjR2NR?=
NCI-ADR-RES	NXX0U2liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\vfYtbUUN3ME2xNlc{NjNyINMxJFE6OS5{MDDuUS=>	NVH1XIY6OjN7NkK0OFU>
MCF7	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PFTmlEPTB;NT6xNUDDuSBzLkS3JI5O	M2L4TlI{QTZ{NES1
MCF7-FLV1000	NUPDWndjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXlflNLUUN3ME2zPVMvOThiwsGgO\|QvQDNibl2=	M1W4OVI{QTZ{NES1
S1	NVTVdYg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHQTWM2OD1{ND6zNEDDuSB2Lke1JI5O	MUCyN\|k3OjR2NR?=
S1-M1-80	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnG3TWM2OD1{NkGuNFYhyrFiNEiuNlUhdk1?	NITkOIYzOzl4MkS0OS=>
CORL-23/P	NEKxVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTRwM{igxtEhOS5{NTDuUS=>	MWWyN\|k3OjR2NR?=
CORL-23/R	MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrBPJJZUUN3ME21MlE3KMLzIEGuPFMhdk1?	M1T5b\|I{QTZ{NES1
NIH3T3	NH\XZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrSTWM2OD12MD62NEDDuSB2Lkm3JI5O	NWTxTmh[OjN7NkK0OFU>
NIH3T3-G185	M{W5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTJ2MUOuOFAhyrFiNEKzMlY3KG6P	NGDwUoszOzl4MkS0OS=>
pcDNA-HEK293	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjvN5lKSzVyPUKuO\|UhyrFiMD62O{BvVQ>?	Ml7HNlM6PjJ2NEW=
MDR19-HEK293	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfITWM2OD16NT61NEDDuSBzMz62O{BvVQ>?	M3vYdFI{QTZ{NES1
R482-HEK293	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEOyb4ZKSzVyPUK1Mlk4KMLzIESuPVUhdk1?	MVOyN\|k3OjR2NR?=
MRP1-HEK293	NGjhOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrBb4pKSzVyPUKuPVkhyrFiMT60PUBvVQ>?	MnLsNlM6PjJ2NEW=
SF188	MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX3NVAuOTByIH7N	MYKyOE06PiCq	MWPEUXNQ	Ml;nbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj2g[IVx\WSnboSgcYFvdmW{	MlzENlM5QDd4NEW=
T98G	M2jiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnaOlB6OTBvMUCwJI5O	NEXJV\|czPC17NjDo	NXrBflV7TE2VTx?=	M17teolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHPvcoNmdnS{YYTpc44uKGSncHXk[Y51KG2jbn7ldi=>	M3fsclI{QDh5NkS1
DU145	NVO0cFZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVvEUXNQ	MUjJR\|Ux6oj:NkCgcm0>	MXqyN\|g5PDR{OB?=
LNCaP	NVjyUFhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkT4SG1UVw>?	MoHiTWM2OOLKvEe1JI5O	NYLMWmxDOjN6OES0Nlg>
PC3	NHftcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWnEU\|doTE2VTx?=	M333TmlEPTEkiMyxO\|Uhdk1?	NWPTb4V{OjN6OES0Nlg>
RT4	M2Lsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrCVo1WUUN3ME2yO{4zOSCwTR?=	MkW4NlM4QTJ4M{m=
5637	NVK3NlBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTRfnhKSzVyPUS1MlQ4KG6P	M3ToOFI{Pzl{NkO5
T24	NVX5VolbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTd7LkGyJI5O	MYmyN\|c6OjZ\|OR?=
MCF7	MXHGeY5kfGmxbjDBd5NigQ>?	NUL1OIh2OTByIH7N	NHPLem0yKGh?	NHf1OGJFVVOR	NXK1fXY2emWmdXPld{B1cGViaX7keYN1cW:wIH;mxsBIemWkMT\|CpHNoczFuwrDQd\|ItyqCVZYLwbY5iOyxiYX7kxsBYcXOyMh?=	NYTybYlEOjN5N{CyOFQ>
KB-V1	M4XHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTNwOUKg{txO	MWKyN\|U6OzF7Nh?=
Hec50co	M3\NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTVibl2=	MUKyN\|E1PjZ6Nx?=
MDA-MB-468	NIrkXlVCeG:ydH;zbZMhSXO\|YYm=	M3fDeVEwPS9zMDDuUS=>	MYGyOE81QC95MjDo	NWq1N255TE2VTx?=	MofybY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXvKSWFbOjNzNESyPVQ>
MCF10A	NET4cZhCeG:ydH;zbZMhSXO\|YYm=	MYexM\|UwOTBibl2=	M{P2RVI1NzR6L{eyJIg>	MWLEUXNQ	MYTpcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NGDoNGUzOzF2NEK5OC=>
Huh-7	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\kfIEyNzFyL{GwNE8yODByIH7N	MnvFOFghcA>?		M1LuWYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh\G:\|ZT3k[ZBmdmSnboTsfS=>	NGr0bWczOjd2NUW4Oy=>
Daoy	NVf3UY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH:2XXoyNjh5NT2yOFAhdk1?	MkCxO\|IhcA>?	M1KzeGROW09?	M{LsWmlEPTB;NTDuUS=>	NWfqO4h1OjJ\|OUCyO\|k>
ONS-76	M{PLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe0S2MyNjh5NT2yOFAhdk1?	MYC3NkBp	NFnYO3JFVVOR	MV3JR\|UxRTdwNTDuUS=>	MkfkNlI{QTB{N{m=
SUM 149	NF75NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\S[GRMOC1zMECgcm0>	MVy3NkBp		NFzNSHBqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	MnHXNlI{ODl7M{m=
MDA-MB-231	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LzN\|AuOTByIH7N	MlXLO\|IhcA>?		M2HVPIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MnnrNlI{ODl7M{m=
HR5	M{Dk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVuwMVExOCCwTR?=	NH3vZoY4OiCq		NFLMXmpqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	NXq2eGIyOjJ\|MEm5N\|k>
BT-474-M1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknkNE0yODBibl2=	MY[3NkBp		NF\HVWRqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	MVqyNlMxQTl\|OR?=
AU565	M4HO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvCeodNOC1zMECgcm0>	MVe3NkBp		M3jxO4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MYmyNlMxQTl\|OR?=
T47D	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY[wMVExOCCwTR?=	NWHZT\|hbPzJiaB?=		M{n6c4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NVzRWFNsOjJ\|MEm5N\|k>
MCF7	Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPsNE0yODBibl2=	M{XzbVczKGh?		M2e2colvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	NYjGPWo2OjJ\|MEm5N\|k>
HCT116p53(+/+)	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILnZ5gyOC1zMECwJI5O	MmrhNlQwPDhiaB?=		NVX2eYR7cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	MWeyNlI3OjF5MR?=
HCT116p53(-/-)	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTmU2FHOTBvMUCwNEBvVQ>?	MYOyOE81QCCq		MXPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=>	Ml;ONlIzPjJzN{G=
HeLa	NYHRfmxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HhTVExNTFyMDDuUS=>	MXK0PEBp	MkXnSG1UVw>?	NF\me5BKSzVyPUWyMlkhdk1?	MVeyNlA5ODJ\|NR?=
HeLa	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV:xNE0yODBibl2=	NEK2fnc4OiCq	M2r6e2ROW09?	MULJR\|UxRTVyLkWgcm0>	NV;Jd3NrOjJyOECyN\|U>
GBC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2juXlczKGh?		MWjJR\|UxRTF2Lke4JI5O	NWXod4JFOjF7NkW3N\|k>
GB-CL-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVy3NkBp		M4jwZWlEPTB;NT6yNkBvVQ>?	MonuNlE6PjV5M{m=
Mz-ChA-2	NH3hbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmOyO\|IhcA>?		MkjOTWM2OD1\|LkOxJI5O	MnTZNlE6PjV5M{m=
TGBC1-TKB	M1;XXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4PrSlE1PCCq		MULJR\|UxRTZwN{Kgcm0>	NUHrNJd2OjF7NkW3N\|k>
Wittier	NFnObXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mm\3O\|IhcA>?		NHrRRlhKSzVyPUOuNlYhdk1?	MYOyNVk3PTd\|OR?=
H-1	MoDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVvDXW86PzJiaB?=		MnflTWM2OD17LkW0JI5O	NIDDPVczOTl4NUezPS=>
HuH-28	NY\5SpFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVHNXll{PzJiaB?=		NVLIVJlSUUN3ME2xNU4yQSCwTR?=	NHfqc3UzOTl4NUezPS=>
NEC	NGG3bWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEnz[FY4OiCq		NGjFUWpKSzVyPUmuPVghdk1?	NWi5WG03OjF7NkW3N\|k>
REB	NVrZfVlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV:3NkBp		NXnLPIVlUUN3ME2xN{42OSCwTR?=	MmXnNlE6PjV5M{m=
CC-LP-1	M{DoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX3FS4R4PzJiaB?=		MVrJR\|UxRTVwOESgcm0>	NH\BUoszOTl4NUezPS=>
CC-SW-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXT0SXBkPzJiaB?=		MVrJR\|UxRTlwNUWgcm0>	MkD4NlE6PjV5M{m=
EGI-1	MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3fkXlczKGh?		MluyTWM2OD1zMD63NkBvVQ>?	MViyNVk3PTd\|OR?=
Sk-ChA-1	M1rhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH7heWw4OiCq		MUPJR\|UxRTF5LkKgcm0>	NI[xSnEzOTl4NUezPS=>
TFK-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXm3NkBp		MWPJR\|UxRTF\|LkS1JI5O	MkfWNlE6PjV5M{m=
786-O	NX\RcIY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXKOU05OCCwTR?=	NU\pdVRxQTZiaB?=	M3jhOmhEdA>?	M3;HVpN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	NU[ybol6OjF4NEKzO\|Q>
A498	NVTpWmx1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn0OU05OCCwTR?=	NYLXTJJGQTZiaB?=	NHL5fXJJS2x?	NUjqXJdye3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MmnUNlE3PDJ\|N{S=
ACHN	NHPjc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37MUlUuQDBibl2=	M1ywT\|k3KGh?	NEPTZoRJS2x?	NIn0PJR{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	M{\rdlIyPjR{M{e0
Caki-1	M4DZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUK1MVgxKG6P	NG\R[246PiCq	M3vDcmhEdA>?	M4fNUJN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	M2e1ZVIyPjR{M{e0
SN12C	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnv2OU05OCCwTR?=	MlKwPVYhcA>?	MnyyTGNt	MXvzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	MU[yNVY1OjN5NB?=
HMC-1.1	M2PIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDLZ5V6OS1zMECwJI5O	NVjoOYFOPzJiaB?=		NX3XR\|NRcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	MX2yNVI1OjF6OR?=
HMC-1.2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPPfYhIOS1zMECwJI5O	M1;2T\|czKGh?		MY\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	M4\OXVIyOjR{MUi5
C2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXoPIYyNTFyMECgcm0>	MnzZO\|IhcA>?		NWf0bGZEcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	MWmyNVI1OjF6OR?=
CHP-212	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYCxMVEzPSCwTR?=	MkTZNlQuOTJyIHi=		MU\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	M1zUVFIyOTZ7MkSy
IMR-32	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTHNU0yOjVibl2=	MXuyOE0yOjBiaB?=		NFTZR5FqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MX2yNVE3QTJ2Mh?=
Kelly	M1\KWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PmWFEuOTJ3IH7N	Mm\3NlQuOTJyIHi=		MYfpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NVnq[5hNOjFzNkmyOFI>
SH-EP	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTOWmJjOS1zMkWgcm0>	NIj0Z3kzPC1zMkCgbC=>		MWTpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NFHwW3YzOTF4OUK0Ni=>
SH-SY5Y	M{nlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1q5ZVEuOTJ3IH7N	MV:yOE0yOjBiaB?=		MVTpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	M{HWeVIyOTZ7MkSy
SK-N-AS	MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYixMVEzPSCwTR?=	M3TOS\|I1NTF{MDDo		MXjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	Mmq1NlEyPjl{NEK=
SK-N-BE	NIewcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUixMVEzPSCwTR?=	M2rHSlI1NTF{MDDo		M{X4eYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	M33IRlIyOTZ7MkSy
KG1	M3zaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NESyWmYyNzFyL{GwNEBvVQ>?	Moj0O\|IhcA>?	NHPydHFFVVOR	NXr6SlBPcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	Mon2NVk1PTh\|NUi=
U937	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrBNU8yOC9zMECgcm0>	NVv4RWFEPzJiaB?=	MmDrSG1UVw>?	MYjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	M2n3WlE6PDV6M{W4
CAL62	NWjHPWVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rHblAvOS1zMECgcm0>	NHX0XJo4OiCq	MYLEUXNQ	MVTFR\|UxRTFwNDDuUS=>	MnLlNVkzOjN3NUO=
OCUT-1	M{C4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUOwMlEuOTByIH7N	M2PG[\|czKGh?	NG\WZplFVVOR	M4\qWGVEPTB;Mj6zJI5O	MWOxPVIzOzV3Mx?=
8505C	NHSyZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jCNFAvOS1zMECgcm0>	MXu3NkBp	MYLEUXNQ	NXXPOoNkTUN3ME2zMlIhdk1?	NGS3e5cyQTJ{M{W1Ny=>
ACT-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvWNE4yNTFyMDDuUS=>	MoTRO\|IhcA>?	MlWySG1UVw>?	NY\FW5RHTUN3ME21MlQhdk1?	NYjURnNHOTl{MkO1OVM>
SW1736	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO3SpUxNjFvMUCwJI5O	NWjmN3VEPzJiaB?=	M1:ySmROW09?	NFTRXm5GSzVyPUWuOkBvVQ>?	NFfTSI4yQTJ{M{W1Ny=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	+ Expand Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 91 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 91 Publications

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)